Mediqstar, a Korean AI healthcare company, announced on the 23rd that it has secured Series A investment from Pathfinder H. The investment amount was not disclosed. With this funding, Mediqstar plans to accelerate its global expansion in tuberculosis diagnostics, led by its AI-powered diagnostic device MycoScan, and advance its AI CRO (Contract Research Organization) business.

Mediqstar’s flagship technology, MycoScan, simplifies the traditionally complex tuberculosis diagnostic process and improves accuracy, significantly enhancing efficiency in medical settings. Starting this year, the company will expand into overseas markets, including Vietnam, to provide better diagnostic services to tuberculosis patients in regions heavily affected by the disease.

Pathfinder H stated, “We decided to invest in Mediqstar after evaluating its innovative technology and potential in the global healthcare market. We expect Mediqstar to grow into a leading company in the global AI healthcare market through its AI CRO business and expansion into international tuberculosis diagnostic markets.”

Seung-jae Yoo, CEO of Mediqstar, said, “This investment provides a foundation for Mediqstar to leap forward as a leader in AI-based medical innovation. Through the global expansion of our tuberculosis diagnostics business, we aim to contribute to improving global public health. Additionally, our AI CRO business will revolutionize the clinical trial process, which traditionally requires high costs and lengthy timelines, positioning us as a leading AI healthcare company.”